Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple urine test could spot pancreatic cancer early

NCT ID NCT07587866

Diagnosis Sponsor: Urteste S.A Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This study will test a new urine test called Panuri to see how well it can detect pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. About 1100 adults with symptoms that might suggest pancreatic cancer will provide urine samples for analysis. The goal is to see if this simple, non-invasive test can accurately identify cancer, potentially leading to earlier diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Panuri test (urine-based diagnostic assay)
What this could lead to
If successful, this could provide a simple, non-invasive urine test to help detect pancreatic cancer earlier in people with symptoms.
What could go wrong
This is an early-stage diagnostic study, not a treatment trial. The test may not be accurate enough to replace current methods, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients presenting to healthcare providers with symptoms supporting a clinical suspicion of pancreatic cancer. The enriched arm will recruit sequential patients scheduled for pancreatic histopathological assessment.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Arm 1 (Target Arm): * Adults 18 years and older * Presenting with symptoms supporting a clinical suspicion for pancreatic cancer by the healthcare provider, including but not limited to jaundice, abdominal or back pain, fatty stools, unexplained weight loss, loss of appetite, chronic fatigue, nausea, vomiting, indigestion, bloating, gas, diarrhea, constipation, itching, dark urine, fever, and swelling of the legs. * Arm 2 (Enriched Arm): * Adults 18 years and older * Scheduled for a procedure involving pancreatic histopathological assessment due to suspicion of pancreatic cancer. Exclusion Criteria: * For subjects in the enriched arm, imaging results are highly suspicious for non-PDAC pancreatic cancer. * Patients enrolled in a pancreatic cancer screening program. * Prior diagnosis of pancreas malignancy, including pathological diagnoses and suspicion of pancreatic cancer based on clinical, histopathological or radiological results. Exceptions include: pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous neoplasms (IPMN), mucinous cystadenoma of the pancreas (MCN), serous cystadenomas (SCN) or other benign pancreatic lesions and cystic lesions without features suggestive of malignancy. * History of pancreatic resection * Presenting with concurrent symptoms or suspicion of urinary tract infection Diagnosis of any urinary tract infection within the last 30 days, except for cases that have been resolved with antibiotics discontinued at least 14 days prior to enrollment * Diagnosed with stage 3b to 5 chronic kidney diseases (CDK3b-CDK5), acute kidney disease in last 3 months, nephrotic syndrome in the last 6 months, or other kidney diseases associated with proteinuria * Diagnosed with any conditions that increase bilirubin levels within the last 6 months * Self-reported or documented elevated blood bilirubin levels within the past 3 months, defined as exceeding 1.5 times the upper limit of normal specific to the test laboratory * Diagnosis of any cancer within the past 5 years * Chemotherapy or anti-neoplastic therapy within the last 5 years * Any medical or psychological conditions that preclude compliance with study procedures. * Patients without any clinical signs or symptoms of pancreatic cancer * Inability to provide written informed consent. * Pregnant or breastfeeding women * Current participation in another drug or device study or planned participation prior to completion of sample collection procedures (i.e., approximately 1.5 months)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic ductal adenocarcinoma (PDAC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic ductal adenocarcinoma (PDAC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    27 sites in 3 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • 4 Wojskowy Szpital Kliniczny z Polikliniką Samodzielny Publiczny Zakład Opieki Zdrowotnej we Wrocławiu

    RECRUITING

    Wroclaw, 50-981, Poland

  • Bács-Kiskun Vármegyei Oktatókórház

    NOT_YET_RECRUITING

    Kecskemét, 6000, Hungary

  • Békés Megyei Központi Kórház Dr. Réthy Pál Tagkórház

    NOT_YET_RECRUITING

    Békéscsaba, 5600, Hungary

  • Centrum Badawcze Panaceum Agnieszka Brzezicka, Magdalena Lenkiewicz Sp. z o.o.

    NOT_YET_RECRUITING

    Malbork, 82-200, Poland

  • Centrum Medyczne K2J2

    NOT_YET_RECRUITING

    Wołomin, 05-200, Poland

  • Comarch Healthcare S.A. Centrum Medyczne iMed24

    NOT_YET_RECRUITING

    Krakow, 31-864, Poland

  • Csőszi Endoszkópos Kft.

    RECRUITING

    Kecskemét, 6000, Hungary

  • Gastroenterologia ed Endoscopia digestiva Ospedale "Morgagni - Pierantoni" di Forlì

    NOT_YET_RECRUITING

    Forlì, 47121, Italy

  • Metabolica Sp. z o.o.

    RECRUITING

    Tarnów, 33-100, Poland

  • Military Institute of Medicine - National Research Institute

    RECRUITING

    Warsaw, 04-141, Poland

  • Niepubliczny Zakład Opieki Zdrowotnej "Diagmed" J.Bajorek, N.Kopeć Spółka Jawna

    RECRUITING

    Dąbrowa Tarnowska, 33-200, Poland

  • Onkomedica Sp. z o.o.

    RECRUITING

    Warsaw, 01-934, Poland

  • OŚRODEK MEDYCZNY "OSTEOMED" S.C. Mirosław Szlachcic, Ewa Szlachcic

    ACTIVE_NOT_RECRUITING

    Krakow, 30-074, Poland

  • Ośrodek Badań Klinicznych BD Research Sp. z o.o.

    RECRUITING

    Iława, 14-200, Poland

  • Pancreas Translational and Clinical Center IRCCS Ospedale San Raffaele

    NOT_YET_RECRUITING

    Milan, 20132, Italy

  • Pankreász Betegségek Intézete Semmelweis Egyetem

    NOT_YET_RECRUITING

    Budapest, 1083, Hungary

  • Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji

    ACTIVE_NOT_RECRUITING

    Warsaw, 02-507, Poland

  • Pleszewskie Centrum Medyczne w Pleszewie Sp. z o.o.

    NOT_YET_RECRUITING

    Pleszew, 63-300, Poland

  • Przychodnia KOPERNIKA Sp. z o.o.

    RECRUITING

    Grudziądz, 86-300, Poland

  • SC Chirurgia Generale 1 Fondazione IRCCS Policlinico "San Matteo"

    NOT_YET_RECRUITING

    Pavia, 27100, Italy

  • SPZOZ Uniwersyteckie Centrum Kliniczne Klinika Chirurgii Onkologicznej, Transplantacyjnej i Ogólnej

    NOT_YET_RECRUITING

    Gdansk, 80-214, Poland

  • Salve Medica Sp. z o.o.

    RECRUITING

    Lodz, 91-211, Poland

  • Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ Dr. Bugyi István Szentesi Multidiszciplináris Centrum

    NOT_YET_RECRUITING

    Szentes, 6600, Hungary

  • UOC Gastroenterologia Azienda Ospedaliero Universitaria Pisana

    NOT_YET_RECRUITING

    Pisa, 56124, Italy

  • Unità Operativa Complessa di Endoscopia Digestiva Chirurgica Fondazione Policlinico Universitario A. Gemelli IRCCS

    NOT_YET_RECRUITING

    Roma, 00168, Italy

  • Unità Operativa di Chirurgia Pancreatica IRCCS Istituto Clinico Humanitas

    NOT_YET_RECRUITING

    Rozzano, 20089, Italy

  • Unità di Oncologia Medica Gastrointestinale e Tumori Neuroendocrini Istituto Europeo di Oncologia (IEO)

    NOT_YET_RECRUITING

    Milan, 20141, Italy

  • Uniwersytecki Szpital Kliniczny nr 1 im. Prof. Tadeusza Sokołowskiego PUM w Szczecinie

    ACTIVE_NOT_RECRUITING

    Szczecin, 71-252, Poland

  • Wielkopolskie Centrum Onkologii im. Marii Skłodowskiej-Curie

    ACTIVE_NOT_RECRUITING

    Poznan, 61-866, Poland

  • Wielospecjalistyczny Szpital Medicover

    NOT_YET_RECRUITING

    Warsaw, 02-972, Poland

  • Wojewódzki Szpital Specjalistyczny im. Janusza Korczaka Sp. z. o.o.

    ACTIVE_NOT_RECRUITING

    Słupsk, 76-200, Poland

  • Zanamed Medical Clinic Sp. z o.o.

    RECRUITING

    Lublin, 20-601, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.